Oncology Times - OncTimes Talk podcast

Player FM - Internet Radio Done Right

23 subscribers

Vor neun Jahren hinzugefügt

Inhalt bereitgestellt von Oncology Times. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Oncology Times oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

Peak Travel

1
Why Petra Needs Its People 28:39

vor 18 hours28:39

Später Spielen

Listen

Gefällt mir

Geliked

28:39

For centuries, members of the B’doul Bedouin tribe lived in the caves around the ancient city of Petra, Jordan. Then, in the 1980s, the government forced the tribe to move in the name of preserving the geological site for tourists. But if the residents are forced to leave, and if their heritage has been permanently changed, then what exactly is being preserved? Learn about your ad choices: dovetail.prx.org/ad-choices…

Oncology Times - OncTimes Talk

Serie-Home•Feed

Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!

193 Episoden

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Oncology Times - OncTimes Talk

23 subscribers

updated vor 6 Tagen

Serie-Home•Feed

Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!

193 Episoden

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Alle Folgen

1
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk 12:53

vor 6 Tagen12:53

12:53

Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients. Moghul told the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco how the study addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.…

1
Striking Microbiome Bacterial Population Differences Distinguish Metastatic Prostate Cancer From Non-Metastatic Disease 8:40

vor 29 Tagen8:40

8:40

At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial species in the gut microbiomes of patients with metastatic prostate cancer that distinguished them from those with non-metastatic disease. This was in the PROMISE-JAPAN study with 869 Japanese patients. After talking about his group’s new data, lead researcher Koji Hatano, MD, a urologist from Osaka University in Japan, discussed the insights this has given doctors into the metastatic process and potential ways of modifying it.…

1
Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer 9:41

vor 29 Tagen9:41

9:41

At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therapy did not improve outcomes when added to surgery for patients with high-risk prostate cancer. Using 2 years of androgen deprivation therapy after radical prostatectomy in high-risk patients with undetectable postoperative PSA did not significantly improve metastasis-free survival. First author François Rozet, MD, a senior surgeon in the Department of Urology at the Institut Mutualiste.…

1
Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance 10:08

vor 29 Tagen10:08

10:08

A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance. A research study using APP4 was reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. First author Ruben Del Castillo, MD, a radiation oncologist from the Sunnybrook Health Sciences Centre in Toronto, Canada, shared the details.…

1
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities 12:53

vor 29 Tagen12:53

12:53

Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group’s findings from the Man Van study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients conducted in Greater London. Moghul told the 2025 ASCO Genitourinary Cancers Symposium in San Francisco how the study had addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.…

1
Episode 3, Better Informed Patient Journeys 12:27

vor 5 weeks12:27

12:27

In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. David O’Malley, and Bobbie R, an ovarian cancer patient. Dr. O’Malley will highlight how HRD testing empowers ovarian cancer patients to make more informed decisions with their doctors to help guide their treatment journey, and Bobbie will provide insight into her experience with HRD testing. Dr. David O’Malley is a professor in the department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James. Bobbie is a stage 3C ovarian cancer patient who lives in Rochester, New York. Bobbie is an animal rights activist, vegetarian, and exerciser who recently retired from the healthcare field, having worked as a registered nurse and owner of a healthcare staffing firm. Following her diagnosis in July of 2021, Bobbie participated in biomarker testing which indicated that she was breast cancer gene (BRCA) negative and homologous recombination deficiency (HRD) positive. After undergoing surgery and chemotherapy as first-line treatment, Bobbie’s oncologist explained that she was eligible for a poly-ADP ribose polymerase (PARP) inhibitor due to her HRD status and on March 7, 2022, Bobbie started on a PARP inhibitor for maintenance treatment. As she continues treatment in 2024, Bobbie celebrates over 45 years of marriage with her husband and looks forward to traveling the United States, reading good books, and spending time with her dogs. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com. This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokespeople's opinions and experiences.…

1
Episode 2, HRD Testing Deep-Dive 7:23

vor 5 weeks7:23

7:23

In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com . This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.…

1
Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer 16:40

vor 5 weeks16:40

16:40

In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches. Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Associate Director of Clinical Research and Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. A graduate of the University of Washington School of Medicine, WA, Dr. Moore completed her residency in gynecology at the University Health Center of Pittsburgh in Pittsburgh, PA and completed a fellowship in gynecologic oncology at the University of Oklahoma College of Medicine in Oklahoma City, OK. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care. For more information, visit: https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com . This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokeperson's opinions and experience.…

1
KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma 7:33

vor 10 weeks7:33

7:33

The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable advanced or metastatic melanoma. Results from the study were reported at the European Society for Medical Oncology (ESMO) 2024 Annual Congress, held in Barcelona, Spain.…

1
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified 16:09

vor 11 weeks16:09

16:09

Although one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated with drugs that inhibit WRN, the effectiveness of such an approach has been limited by resistance. However, researchers identified the Cys727 mutation as being solely responsible for WRN inhibitor resistance. This potentially opens the door to using WRN inhibitors in the cancer clinic by inactivating this resistance gene. At the EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium Gabriele Picco, PhD, Senior Staff Scientist in the Translational Cancer Genomics Team at the Wellcome Sanger Institute’s Genome Campus, reported findings about WRN resistance mechanisms that may clear the path to introducing WRN inhibitors to the cancer clinic to fight microsatellite unstable cancers.…

1
Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development 9:21

vor 12 weeks9:21

9:21

A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location. The ESMO Tumour-Agnostic Classifier and Screener was the result of work by a multidisciplinary team of international experts led by the ESMO Precision Medicine Working Group. At the conference, Benedikt Westphalen, MD, a medical oncologist and molecular biologist who is Head of the Precision Oncology Program at the University of Munich in Germany, talked about the details with Oncology Times correspondent Peter Goodwin.…

1
Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma 7:25

vor 12 weeks7:25

7:25

Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to immune checkpoint inhibition appeared to bring better rates of overall survival than saving immunotherapy for use as salvage treatment later on. The ESMO 2024 Annual Congress heard from the randomized Phase II ImmunoCobiVem trial that a switch to immunotherapy after only 3 months treatment with drugs targeted to the mutation gave equivalent or better survival than continuing with targeted therapy.…

1
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified 7:33

vor 12 weeks7:33

7:33

1
Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer 6:59

vor 12 weeks6:59

6:59

A clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYNOTE-A18 study of immunotherapy together with concurrent chemoradiotherapy among 1,060 patients who had newly diagnosed, previously untreated high-risk locally advanced cervical cancer. A multinational team of researchers, led from Italy, reported findings at the ESMO Congress 2024. There was a statistically significant increase in 36-month overall survival in patients treated with pembrolizumab, in addition to chemoradiotherapy, in comparison to those in the control group who received standard chemoradiation alone.…

1
The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front 13:54

vor 13 weeks13:54

13:54

In this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences and Clinical Professor of Pathology at University of California, San Francisco, to discuss the importance of ultra-comprehensive genomic profiling in advanced cancer therapy selection. The two talk about the OncoExTra® test from Exact Sciences, which includes whole-exome DNA sequencing and whole-transcriptome RNA sequencing, and how the latest updates to industry guidelines will continue to influence approaches to cancer care.…

Willkommen auf Player FM!

Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.